# OnCo record paper-fight-202-pemigatinib-lancet-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-fight-202-pemigatinib-lancet-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-fight-202-pemigatinib-lancet-oncol-2020" ;
  schema:name "FIGHT-202: pemigatinib for previously treated cholangiocarcinoma with FGFR2 fusions or rearrangements"@en ;
  schema:description "The FGFR inhibitor pemigatinib shrank tumours in more than a third of patients with previously treated intrahepatic cholangiocarcinoma carrying FGFR2 fusions, the first targeted drug approved for the disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-fight-202-pemigatinib-lancet-oncol-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(20)30109-1>, <https://pubmed.ncbi.nlm.nih.gov/32203698/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(20)30109-1> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Abou-Alfa GK, Sahai V, Hollebecque A, et al." ;
  onco:cancers <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/> ;
  onco:drugs <https://onco.cc/drugs/pemigatinib/> ;
  onco:trials <https://onco.cc/trials/fight-202/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .